EUVIMEDEUVIMED entdecken
Crossref

Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal–temozolomide therapy for glioblastoma

Junhao Pan, Meilin Qiao, Yuan Chen, Ruibing Yu, Qirui Fang, Yuteng Chu, Xiaotian Wang, Jie Shen, Xuanrong Sun

Acta Biomaterialia · 2026-08 · 219 · 604-617

DOI: 10.1016/j.actbio.2026.06.037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-08. Verfasst von Junhao Pan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of Tec…. Hauptthemen laut MEDLINE: Gold, Glioblastoma, Temozolomide, RNA, Small Interfering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) remains highly lethal, and standard temozolomide (TMZ) therapy is undermined by O6-methylguanine-DNA-methyltransferase (MGMT)-driven resistance. Herein, we present a Fe3+-responsive aggregable gold nanoplatform (siMGMT@P-T D-Q Au NP) for systemic delivery of MGMT-targeting siRNA (siMGMT) and enables on-demand photothermal therapy (PTT). The platform reconciles the size-performance trade-off of siMGMT@P-T D-Q Au NP: it preserves a small hydrodynamic size during circulation to promote blood-brain barrier (BBB) penetration and tumor access. When in the tumor microenvironment, Fe3+-induced siMGMT@P-T D-Q Au NP rapid aggregation promotes plasmonic coupling, red-shifts near-infrared absorption, and markedly amplifies 808-nm photothermal ablation. Concurrently, Furin triggers siMGMT release to suppress MGMT and resensitize tumor cells to TMZ. The proposed sequential regimen comprises intravenous administration of siMGMT@P-T D-Q Au NP, Fe3+-triggered siMGMT@P-T D-Q Au NP aggregation to enhance PTT to kill tumors, and subsequent oral TMZ as maintenance therapy. This strategy integrates gene silencing to reverse chemoresistance, Fe3+-responsive aggregable enhancement of PTT, and standard-of-care chemotherapy, addressing key delivery barriers while aiming to improve therapeutic breadth with minimal invasiveness. STATEMENT OF SIGNIFICANCE: Our research covers the following highlights: 1. The constructed size-adaptive Au NP first crosses the blood-brain barrier as small particles and then accumulates as larger ones to enhance therapy. 2. The enhanced photothermal conversion efficiency of Au NP enables synergistic photothermal therapy against glioma. 3. Downregulation of drug-resistance gene MGMT maximizes the therapeutic efficacy of temozolomide. 4. The combined strategy of gene silencing and photothermal-chemotherapy achieves enhanced glioma treatment. Over all, this platform represents an innovative size-adaptive gold nanoplatform that achieves siRNA-mediated reversal of TMZ chemoresistance and enables synergistic photothermal therapy against glioblastoma, offering a paradigm for the future development of integrated, multimodal glioma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoldGlioblastomaTemozolomideRNA, Small InterferingMetal NanoparticlesDrug Resistance, NeoplasmBrain NeoplasmsPhotothermal TherapyIronAnimalsHumansCell Line, TumorMiceMice, Nude

Stichwörter der Autor:innen

Chemoresistance reversalFe(3+)-responsive aggregable gold nanoparticleGlioblastomaPhotothermal therapysiMGMT

Substanzen

GoldTemozolomideRNA, Small InterferingIron

Autor:innen und Institutionen

  • Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
  • Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, China. Electronic address: shenjie25@zstu.edu.cn.
  • Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China; Zhejiang-Egypt Joint Laboratory on In…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Pan, J., Qiao, M., Chen, Y., Yu, R., Fang, Q., Chu, Y., Wang, X., Shen, J., & Sun, X. (2026). Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal–temozolomide therapy for glioblastoma. Acta Biomaterialia, 219, 604-617. https://doi.org/10.1016/j.actbio.2026.06.037

Vancouver

Pan J, Qiao M, Chen Y, Yu R, Fang Q, Chu Y, et al. Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal–temozolomide therapy for glioblastoma. Acta Biomaterialia. 2026;219:604-617. doi:10.1016/j.actbio.2026.06.037

BibTeX
@article{Pan2026,
  author = {Pan, Junhao and Qiao, Meilin and Chen, Yuan and Yu, Ruibing and Fang, Qirui and Chu, Yuteng and Wang, Xiaotian and Shen, Jie and Sun, Xuanrong},
  title = {Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal–temozolomide therapy for glioblastoma},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {219},
  pages = {604--617},
  doi = {10.1016/j.actbio.2026.06.037}
}
Kostenlos starten →